Indeed, a reduction in the incidence of serious hyperkalaemia (potassium > 6.0 mmol/L) of approximately 15% with SGLT2 inhibitors has been confirmed in a large individual participant data meta-analysis of people with T2D at high CV risk and/or with CKD (85). Here, SLC5A2 is linked to type 2 diabetes mellitus.